Capricor Therapeutics (NASDAQ:CAPR) Trading 12% Higher - Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s stock price shot up 12% on Wednesday . The company traded as high as $10.98 and last traded at $11.39. 453,155 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 1,974,308 shares. The stock had previously closed at $10.17.

Analysts Set New Price Targets

Several brokerages have recently commented on CAPR. Roth Capital reaffirmed a "buy" rating and set a $31.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. Jones Trading cut their price target on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, June 25th. B. Riley started coverage on Capricor Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $21.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $24.00 price objective (down previously from $77.00) on shares of Capricor Therapeutics in a research report on Friday. Finally, Oppenheimer cut their price objective on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $26.33.

Capricor Therapeutics Price Performance

The business's 50-day moving average price is $10.42 and its two-hundred day moving average price is $12.16. The company has a market capitalization of $346.30 million, a P/E ratio of -5.39 and a beta of 0.82.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The company had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same period in the prior year, the firm posted ($0.31) earnings per share. Research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after purchasing an additional 37,868 shares during the last quarter. Swiss National Bank bought a new stake in Capricor Therapeutics in the 4th quarter valued at about $930,000. Nuveen Asset Management LLC lifted its holdings in shares of Capricor Therapeutics by 392.7% during the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock worth $2,334,000 after acquiring an additional 134,791 shares during the period. Alliancebernstein L.P. bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $183,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Capricor Therapeutics by 22.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 2,361 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.